Insys Therapeutics (INSY) – Research Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for Insys Therapeutics (NASDAQ: INSY):

  • 11/3/2017 – Insys Therapeutics had its price target lowered by analysts at Jefferies Group LLC from $14.00 to $11.00. They now have a “buy” rating on the stock.
  • 10/30/2017 – Insys Therapeutics had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 10/27/2017 – Insys Therapeutics was given a new $8.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 10/25/2017 – Insys Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona. “
  • 10/24/2017 – Insys Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $8.50 price target on the stock. According to Zacks, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona. “
  • 10/19/2017 – Insys Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona. “
  • 10/18/2017 – Insys Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $8.50 price target on the stock. According to Zacks, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona. “
  • 10/11/2017 – Insys Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $14.00 price target on the stock.

Shares of Insys Therapeutics, Inc. (NASDAQ INSY) opened at $5.10 on Monday. Insys Therapeutics, Inc. has a 12-month low of $4.10 and a 12-month high of $15.06.

Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative net margin of 112.56% and a negative return on equity of 9.98%. The firm had revenue of $42.60 million during the quarter, compared to the consensus estimate of $36.90 million. During the same quarter in the prior year, the firm earned $0.13 EPS. Insys Therapeutics’s revenue for the quarter was down 38.4% on a year-over-year basis. research analysts forecast that Insys Therapeutics, Inc. will post -0.62 earnings per share for the current fiscal year.

In other Insys Therapeutics news, CEO Saeed Motahari purchased 5,500 shares of Insys Therapeutics stock in a transaction that occurred on Thursday, August 10th. The stock was purchased at an average price of $8.92 per share, for a total transaction of $49,060.00. Following the transaction, the chief executive officer now directly owns 15,400 shares in the company, valued at $137,368. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder John N. Kapoor Trust Dated Sept purchased 17,500 shares of Insys Therapeutics stock in a transaction that occurred on Friday, August 11th. The stock was acquired at an average price of $8.93 per share, with a total value of $156,275.00. Following the transaction, the insider now owns 31,982 shares in the company, valued at $285,599.26. The disclosure for this purchase can be found here. 67.90% of the stock is owned by corporate insiders.

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

What are top analysts saying about Insys Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Insys Therapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit